We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.
- Authors
Higgs, Elizabeth S; Gayedyu-Dennis, Dehkontee; II, William A Fischer; Nason, Martha; Reilly, Cavan; Beavogui, Abdoul Habib; Aboulhab, Jamila; Nordwall, Jacqueline; Lobbo, Princess; Wachekwa, Ian; Cao, Huyen; Cihlar, Tomas; Hensley, Lisa; Lane, H Clifford
- Abstract
Background Ebola virus RNA persists in the semen of male Ebola survivors for months to years after the acute infection, and male-to-female sexual transmission of the virus is well documented. We investigated whether remdesivir can safely reduce persistence of seminal Ebola virus RNA. Methods We recruited men with persistent seminal Ebola RNA in Liberia and Guinea. Participants were randomized 1:1 to receive intravenous remdesivir (GS-5734; Gilead Sciences) or matching placebo administered once daily by intravenous infusion over 1 hour on 5 consecutive days. Stratification was by country and number of positive (1 or 2) preenrollment semen tests. We evaluated the difference in mean assay negativity rate (ANR), that is, the proportion of negative tests for each participant in each group in the treatment (days 1–28) and follow-up (months 2–6) phases on an intention-to-treat basis. Results We enrolled 38 men from July 2016 through June 2018. The mean treatment phase ANRs were 85% (standard deviation [SD] = 24%) and 76% (SD = 30%) in the remdesivir and placebo arms, respectively (P = .270). The mean follow-up phase ANRs were 96% (SD = 10%) and 81% (SD = 29%) in the remdesivir and placebo arms, respectively (P = .041). The 5-day remdesivir regimen was well tolerated with no safety concerns. Conclusions In this small trial, remdesivir 100 mg/day for 5 days safely reduced the presence of Ebola virus RNA in the semen of Ebola survivors 2 to 6 months after administration. A larger follow-up study is necessary to confirm results. Clinical Trials Registration. NCT02818582
- Subjects
THERAPEUTIC use of monoclonal antibodies; SEMEN; MONOCLONAL antibodies; RNA; PLACEBOS; EBOLA virus; TREATMENT effectiveness; RANDOMIZED controlled trials; BLIND experiment; DESCRIPTIVE statistics; STATISTICAL sampling
- Publication
Clinical Infectious Diseases, 2021, Vol 73, Issue 10, p1849
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciab215